drugset / Trial / NCT00145704
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
Terminated
6 enrolled
State University of New York - Upstate Medical University
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given to growth hormone deficient patients (regardless of current growth hormone replacement therapy status and without changing that status) significantly increases total body bone mineral density during an eighteen month period of treatment combined with calcium and Vitamin D when compared to calcium and Vitamin D treatment alone.
Timeline
- Start
- 2002-06
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risedronate | Small molecule | 35 mg | Oral |
Indications
No indication recorded.